A Better Way

| November 4, 2016

AesculaTech, a USC Viterbi startup, aims to make it easier for glaucoma patients to take eye drops – and keep their sight.

AesculaTech cofounder Niki Bayat (Photos courtesy of AesculaTech)

AesculaTech cofounder Niki Bayat (Photos courtesy of AesculaTech)

A few years back, ophthalmologists diagnosed Niki Bayat’s father with glaucoma, a degenerative eye disease and leading cause of preventable blindness worldwide.

Bayat, a USC Viterbi Ph.D. student in chemical engineering, watched helplessly as her father failed to take his drops three times daily as prescribed. Sometimes he forgot. Sometimes he had difficulty getting them into his eyes. Sometimes he only administered them once or twice a day because of the discomfort they caused.

Bayat, whose research includes developing biomaterials to treat eye trauma, thought there had to be another way. So she decided to develop one.

Bayat cofounded AesculaTech, a biomedical device company spun out of the research labs of Mark Thompson – her doctoral advisor, an expert in new materials for optoelectronics, and co-inventer of the phosphorescent OLEDs now found in displays in mobile devices and televisions worldwide – and Dr. Mark Humayun – the developer of the Argus II, an artificial retina that restores sight to some blind people, with joint appointments at USC Viterbi and Keck School of Medicine of USC. AesculaTech, named after the Greek god of healing or medicine, Asclepius, has developed an application for timed release of glaucoma medication over a 90-day period, reducing medical complications due to noncompliance or incorrect application.

“If people cannot get the medication they need for glaucoma, they will start going blind,” said Bayat, adding that an estimated 120,000 Americans lose their sight annually to the disease. “So it’s very important to have this sustained delivery system.”

Ophthalmologists would inject AesculaGel, a thermally responsive hydrogel, into the tear ducts. There, the gel would harden and deliver glaucoma medicine at regular daily intervals. At the end of three months, doctors would give patients another injection, beginning the process anew.

Although AesculaTech must successfully conduct lengthy FDA approval before it can come to market, the company has already generated excitement.

The Collegiate Inventors Competition, a national contest sponsored by the United States Patent and Trademark Office that honors innovative research and discovery, selected AesculaTech as one of this year’s graduate team finalists. In 2015, the company won second place among 148 participants in USC’s Lloyd Greif Center for Entrepreneurial Studies’ business plan competition. It also took home the silver last year in the Maseeh Entrepreneurship Prize Competition, a business model contest.

“AesculaTech is one of the best to teams to emerge from the MEPC, and it is an honor to continue to encourage and support them in all the ways I can,” said USC Viterbi Professor Peter Beerel, MEPC executive director.

MEPC helped AesculaTech evolve from an idea into a viable startup, Bayat said. Through MEPC, she and cofounder Andrew Bartynski, Ph.D. CE ’16, developed a business plan and learned about customer acquisition and validation.

AesculaTech cofounder Andrew Bartynski

AesculaTech cofounder Andrew Bartynski

“MEPC made it real,” said Bartynski, now AesculaTech’s chief executive officer. “We got more out of that competition than we could have ever asked for. We’re still in touch with the business mentors we were paired with.”

Looking forward, Bayat said she envisions modified AesculaGel being used to deliver drugs to patients with a variety of medical conditions beyond glaucoma. She declines to elaborate, Bayat said, for competitive reasons.

For now, she and Bartynski feel happy just to make a contribution to improving medical care.

“The purpose of engineering is to make the world a better place,” Bartynski said. “So if you’re an engineer and using your skills to help people, I don’t think there’s a higher calling than that.”